24/7 Market News Snapshot 30 September, 2025 – Nuwellis, Inc. Common Stock (NASDAQ:NUWE)

September 30, 2025

DENVER, Colo., 30 September, 2025 (www.247marketnews.com) – (NASDAQ:NUWE) are discussed in this article.
Nuwellis, Inc. is currently experiencing a notable bullish trend, with pre-market shares trading at $3.782, reflecting a remarkable increase of 7.14% from the previous close of $3.530. This surge indicates heightened investor interest and a promising momentum as the current trading volume reaches 991.60K, suggesting robust activity within the market. Analysts view this price movement as potentially indicative of positive sentiment surrounding the company, and traders are encouraged to monitor key resistance levels. If the buying pressure continues, Nuwellis could see further gains in upcoming sessions, with technical indicators currently favoring bullish sentiment.

In conjunction with its market activity, Nuwellis recently announced significant findings from the ULTRA-Peds registry, representing a milestone in pediatric healthcare. This multi-center observational study examined the use of the Aquadex System in critically ill children suffering from acute kidney injury (AKI), fluid overload, and congenital kidney failure—conditions that lack sufficient treatment options. With enrollment of 91 pediatric patients, the ULTRA-Peds registry has generated the largest real-world dataset to date for this vulnerable group.

The outcomes are promising, featuring an impressive 92% survival rate during treatment with the Aquadex System, alongside a 66% discharge rate from hospitals. Furthermore, 86% of treatment circuits were completed without interruption, highlighting the therapy’s effectiveness and tolerability within this challenging demographic. Dr. Michelle Starr, the lead investigator, underscored the urgent need for pediatric-specific medical devices, observing that the high survival rate emphasizes the demand for innovative solutions tailored to young patients.

These findings reinforce Nuwellis’s commitment to advancing pediatric care, particularly through the development of Vivian, a continuous renal replacement therapy (CRRT) system specifically designed for neonates and small children. Funded by a substantial NIH grant, the Vivian program aims to meet the specialized needs of pediatric patients, further demonstrating Nuwellis’s dedication to bridging healthcare gaps and enhancing integrated cardio-renal health solutions.

Related news for (NUWE)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.